{"filing":{"accession_number":"0001171843-26-006796","cik":"0001760854","ticker":"NNBXF","company_name":"Nanobiotix S.A.","form":"6-K","filing_date":"2026-10-26","report_date":"2026-10-24","primary_document":"f6k_102426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1760854/000117184326006796/f6k_102426.htm"},"events":[{"id":37728,"run_id":34770,"accession_number":"0001171843-26-006796","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces final Phase 1 clinical trial data for JNJ-1900 (NBTXR3) in anti-PD-1-resistant melanoma, presented at ESMO 2026. The disclosure reports efficacy metrics (41.7% ORR, 17.8 months median OS) and safety findings from an ongoing clinical study. While this is a material clinical milestone for a late-stage biotech company's lead candidate, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or restatement). It is a material operational/clinical development milestone that would affect investor assessment of the company's pipeline progress and commercial prospects.","company_name":"Nanobiotix S.A.","ticker":"NNBXF","filing_date":"2026-10-26","form":"6-K","submitted_at":null,"items":[{"id":42532,"accession_number":"0001171843-26-006796","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces final Phase 1 clinical trial data for JNJ-1900 (NBTXR3) in anti-PD-1-resistant melanoma, presented at ESMO 2026. The disclosure reports efficacy metrics (41.7% ORR, 17.8 months median OS) and safety findings from an ongoing clinical study. While this is a material clinical milestone for a late-stage biotech company's lead candidate, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or restatement). It is a material operational/clinical development milestone that would affect investor assessment of the company's pipeline progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:03:45.398533+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42532,"accession_number":"0001171843-26-006796","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces final Phase 1 clinical trial data for JNJ-1900 (NBTXR3) in anti-PD-1-resistant melanoma, presented at ESMO 2026. The disclosure reports efficacy metrics (41.7% ORR, 17.8 months median OS) and safety findings from an ongoing clinical study. While this is a material clinical milestone for a late-stage biotech company's lead candidate, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or restatement). It is a material operational/clinical development milestone that would affect investor assessment of the company's pipeline progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:03:45.398533+00:00","company_name":"Nanobiotix S.A.","ticker":"NNBXF","filing_date":"2026-10-26"}]}
